LGALS3 and metabolic dysfunction-associated steatohepatitis: Gal-3 has been associated with inflammation and liver fibrosis and its inhibition was able to reduce fibrosis in preclinical studies of NASH26,27, although in a very recent clinical study the efficacy of Gal-3 inhibition has not been confirmed in human patients with NASH, cirrhosis and portal hypertension28.